Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis
Phase of Trial: Phase III/IV
Latest Information Update: 07 Oct 2017
At a glance
- Drugs Tofacitinib (Primary) ; Adalimumab; Etanercept
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 14 Feb 2017 Planned number of patients changed from 4000 to 4400.
- 21 Oct 2016 This trial is completed in Austria.